Although the development of a PPD medication is commendable, Dr. Yonkers also notes there are several hurdles which need to be addressed.
Dr. Yonkers: Well, I think the first thing to mention is the company that has developed brexanolone is to be commended for developing the first medication for postpartum depression. So that’s good.
There are some problems with it. You alluded to the price. The price of $35,000-$40,000 for the medication alone is a handsome price and will put it out of reach in all likelihood for many women who may need it. We’ve had a lot of discussion in this country about the cost of prescription medications and one could say that this could be a case study in how not to price a new medication.
The second thing about the medication is the really good news is it’s rapid, so it has a rapid onset of action. It needs to be administered in a medical setting such as a hospitalized setting and moms need to be separated from their babies for the infusion period which is 60 hours. It’s not an insignificant period of time but the data show that it endures for 6 months, so that’s good. It’s rapid. Not so good mom has to be separated from her baby and it lasts for 6 months but we don’t know if it lasts beyond 6 months. So, I think what we’ve seen is we’ve seen a lot of innovation, but we also see some hurdles that need to be addressed.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More